(MENAFN- PR Newswire) The nontuberculous mycobacterial infection market size shall grow during the forecast period (2024–2034) due to the launch of upcoming therapies and the increasing cases of NTM Infections. This market is expected to increase at a significant rate.

LAS VEGAS, Sept. 11, 2024 /PRNewswire/ -- DelveInsight's Nontuberculous Mycobacterial Infection Market Insights
report includes a comprehensive understanding of current treatment practices, nontuberculous mycobacterial infection emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into the United States.

Key Takeaways from the Nontuberculous Mycobacterial Infection Market Report

• According to DelveInsight's analysis, the market size for nontuberculous mycobacterial infection
  was found to be USD 360 million in the US in 2023.
• The majority of the market share was of ARIKAYCE , with a revenue of approximately USD 223 million for refractory MAC. This figure is projected to grow further by 2034, driven by continued advancements in treatment and increasing awareness.
• According to DelveInsight's epidemiology model, the total diagnosed prevalent cases of NTM infections were approximately 108K cases in the US in 2023 which are expected to increase during the forecast period (2024–2034) due to several factors.
• Leading nontuberculous mycobacterial infection
  companies such as AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Paratek Pharmaceuticals, Redhill Biopharma, and others are developing novel nontuberculous mycobacterial infection drugs that can be available in the nontuberculous mycobacterial infection market in the coming years.

• The promising nontuberculous mycobacterial infection therapies in the pipeline include Epetraborole, MNKD-101 (clofazimine inhalation suspension), SPR720 (fobrepodacin), NUZYRA (omadacycline), RHB-204, and others.

Discover which therapies are expected to grab the major nontuberculous mycobacterial infection market share @ Nontuberculous Mycobacterial Infection Market Report

Nontuberculous Mycobacterial Infection Overview

Nontuberculous mycobacteria (NTM) infections are diseases caused by bacteria from the Mycobacterium genus, excluding those responsible for tuberculosis (M. tuberculosis complex) or leprosy/Hansen's disease (M. leprae). The American Lung Association notes that NTM bacteria are commonly found in soil, water, and dust around the world. In the US, Mycobacterium avium complex (MAC) is the most common type of NTM bacteria, responsible for most NTM lung disease cases.

NTM lung disease can manifest in two forms based on its progression. The less aggressive form, nodular bronchiectatic disease, primarily affects older women with no smoking history, causing airway inflammation and scarring that leads to frequent respiratory infections such as bronchitis and pneumonia.

Common symptoms of NTM infection include a chronic cough, fatigue, weight loss, night sweats, shortness of breath, coughing up blood or excessive mucus, fever, and frequent respiratory infections. Risk factors for NTM infection include pre-existing lung conditions, impaired ciliary function, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, skin or soft tissue breaches, and immunodeficiency.

Diagnosing and treating NTM infections can be challenging due to the diversity of NTM species and their varying clinical presentations. Accurate diagnosis requires a comprehensive approach that includes reviewing medical history, physical examination, imaging tests (like chest X-rays or CT scans), and microbiological testing. This testing might involve sputum cultures, bronchoscopy with bronchoalveolar lavage, or lung biopsy to identify the specific NTM species involved.

Nontuberculous Mycobacterial Infection Epidemiology Segmentation

The nontuberculous mycobacterial infection epidemiology section provides insights into the historical and current nontuberculous mycobacterial infection patient pool and forecasted trends for the US. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The nontuberculous mycobacterial infection market report
proffers epidemiological analysis for the study period 2020–2034 in the US segmented into:

• Total Prevalent Cases of NTM Infections
• Total Diagnosed Prevalent Cases of NTM Infections
• Gender-specific Cases of NTM Infections
• Species-specific Cases of NTM Infection
• Type-specific Cases of NTM Infections
  
• Severity-specific Cases of NTM Infections
  

Nontuberculous Mycobacterial Infection Treatment Market

Treatment for NTM lung disease generally includes a mix of antibiotics chosen based on the specific NTM strain and the patient's health condition. Fluoroquinolones like ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, and ofloxacin are often recommended. The treatment usually extends over several months to years and requires close monitoring for effectiveness and side effects. Complementary therapies such as airway clearance techniques, nutritional support, and pulmonary rehabilitation can also help manage symptoms and enhance quality of life.

ARIKAYCE is the first therapy approved by the FDA for treating MAC lung disease as part of a combination antibacterial regimen for adults with few or no other treatment options. It is a unique, inhaled formulation of amikacin, an antibiotic traditionally given intravenously, which can cause severe side effects like hearing loss, balance issues, and kidney damage. ARIKAYCE uses Insmed's PULMOVANCE liposomal technology to deliver amikacin directly to the lungs, where it is taken up by lung macrophages, targeting the infection site and providing a controlled, prolonged release while minimizing systemic exposure. It is administered once daily with the Lamira Nebulizer System from PARI Pharma GmbH. The FDA approved ARIKAYCE in January 2018 for adults with MAC lung disease who have limited treatment options.

In 2020, Insmed Incorporated reached a major achievement when ARIKAYCE (amikacin liposome inhalation suspension) was added to the most recent global treatment guidelines for NTM Infections. These guidelines emphasize the importance of incorporating ARIKAYCE into standard treatment, especially for patients with MAC lung disease who have not cleared sputum cultures after at least six months of treatment.

To know more about nontuberculous mycobacterial infection treatment guidelines, visit @ Nontuberculous Mycobacterial Infection Management

Nontuberculous Mycobacterial Infection Pipeline Therapies and Key Companies

• Epetraborole: AN2 Therapeutics
• MNKD-101 (clofazimine inhalation suspension): Mannkind Corporation
• SPR720 (fobrepodacin): Spero Therapeutics
• NUZYRA (omadacycline): Paratek Pharmaceuticals
• RHB-204: Redhill Biopharma

Discover more about nontuberculous mycobacterial infection drugs
in development @ Nontuberculous Mycobacterial Infection Clinical Trials

Nontuberculous Mycobacterial Infection Market Dynamics

The nontuberculous mycobacterial infection market dynamics are expected to change in the coming years. Firstly, the increasing prevalence of NTM infections , particularly among immunocompromised and elderly populations, has amplified the demand for diagnostic and therapeutic solutions . Advancements in molecular diagnostic technologies are also enhancing the ability to identify these infections more accurately and swiftly, further fueling market expansion. Additionally, the rising awareness of NTM infections and the subsequent emphasis on research and development for novel treatment options are contributing to market growth. Moreover, supportive government policies and increased funding for infectious disease research are playing a crucial role in advancing the market.

Furthermore, potential therapies are being investigated for the treatment of nontuberculous mycobacterial infection, and it is safe to predict that the treatment space will significantly impact the nontuberculous mycobacterial infection
market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the nontuberculous mycobacterial infection
market in the 7MM.

However several factors may impede the growth of the nontuberculous mycobacterial infection market. One major challenge is the limited awareness and understanding of NTM infections among healthcare professionals and patients, which affects early diagnosis and treatment. Additionally, the complexity of NTM infections , which often present with symptoms similar to other diseases, complicates the development and approval of effective therapies. High development costs and lengthy clinical trials further restrict pharmaceutical companies' willingness to invest in NTM-specific treatments. Furthermore, the rarity of these infections can lead to a lack of incentive for research and development , resulting in a limited pipeline of new therapies. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact nontuberculous mycobacterial infection
market growth.

Nontuberculous Mycobacterial Infection Market Report Metrics	Details
Study Period	2020–2034
Coverage	The United States
Nontuberculous Mycobacterial Infection Market Market CAGR	13.4 %
Nontuberculous Mycobacterial Infection Market Size in 2023	USD 360 Million
Key Nontuberculous Mycobacterial Infection Companies	AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Paratek Pharmaceuticals, Redhill Biopharma, Insmed, and others
Key Pipeline Nontuberculous Mycobacterial Infection Therapies	Epetraborole, MNKD-101 (clofazimine inhalation suspension), SPR720 (fobrepodacin), NUZYRA (omadacycline), RHB-204, ARIKAYCE (amikacin liposome inhalation suspension), and others

Scope of the Nontuberculous Mycobacterial Infection
Market Report

• Therapeutic Assessment: Nontuberculous Mycobacterial Infection
  current marketed and emerging therapies
• Nontuberculous Mycobacterial Infection
  Market Dynamics:
  Key Market Forecast Assumptions of Emerging Nontuberculous Mycobacterial Infection
  Drugs and Market Outlook
• Competitive Intelligence Analysis:
  SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Nontuberculous Mycobacterial Infection Market Access and Reimbursement

Download the report to understand which factors are driving nontuberculous mycobacterial infection market trends
@
Nontuberculous Mycobacterial Infection Market Trends

Table of Contents

1	Key Insights
2	Report Introduction
3	NTM Infection Market Overview at a Glance
3.1	Market Share (%) Distribution of NTM Infection in 2020
3.2	Market Share (%) Distribution of NTM Infection in 2034
4	Epidemiology and Market Forecast Methodology
5	Executive Summary
6	Key Events
7	Disease Background and Overview
7.1	Introduction
7.2	Classification
7.3	Sign and Symptoms
7.4	Risk Factors
7.5	Pathophysiology
7.6	Diagnosis
7.7	Diagnostic Guidelines
7.7.1	American Thoracic Society (ATS) Diagnostic Guidelines
7.8	Treatment and Management
7.9	Treatment Guidelines
7.9.1	ATS/Infectious Diseases Society of American (IDSA) Treatment Guidelines (2020)
8	Patient Journey
9	Epidemiology and Patient Population
9.1	Key Findings
9.2	Epidemiology and Patient Population
9.3	Assumption and Rationale
9.3.1	Prevalent Cases of NTM Infections
9.3.2	Diagnosed Prevalent Cases of NTM Infections
9.3.3	Gender-specific Cases of NTM Infections
9.3.4	Species-specific Cases of NTM Infections
9.3.5	Type-specific Cases of NTM Infections
9.3.6	Severity-specific Cases of NTM Infections
9.4	The US
9.4.1	Total Prevalent Cases of NTM Infections in the US
9.4.2	Total Diagnosed Prevalent Cases of NTM Infections in the US
9.4.3	Gender-specific Cases of NTM Infections in the US
9.4.4	Species-specific Cases of NTM Infection in the US
9.4.5	Type-specific Cases of NTM Infections in the US
9.4.6	Severity-specific Cases of NTM Infections in the US
10	Marketed Drugs
10.1	ARIKAYCE (amikacin liposome inhalation suspension): Insmed
10.1.1	Product Description
10.1.2	Regulatory Milestone
10.1.3	Other Developmental Activities
10.1.4	Clinical Trials Information
10.1.5	Safety and Efficacy
11	Emerging Drugs
11.1	Key Cross Competition
11.2	Epetraborole: AN2 Therapeutics
11.2.1	Product Description
11.2.2	Other Developmental Activities
11.2.3	Clinical Trials Information
11.2.4	Safety and Efficacy
11.2.5	Analysts' Views
11.3	MNKD-101 (clofazimine inhalation suspension): Mannkind Corporation
11.3.1	Product Description
11.3.2	Other Developmental Activities
11.3.3	Clinical Trials Information
11.3.4	Safety and Efficacy
11.3.5	Analysts' Views
11.4	SPR720 (fobrepodacin): Spero Therapeutics
11.4.1	Product Description
11.4.2	Other Developmental Activities
11.4.3	Clinical Trials Information
11.4.4	Safety and Tolerability
11.4.5	Analysts' Views
11.5	NUZYRA (omadacycline): Paratek Pharmaceuticals
11.5.1	Product Description
11.5.2	Other Developmental Activities
11.5.3	Clinical Trials Information
11.5.4	Analysts' Views
12	NTM Infections: Market Analysis
12.1	Key Findings
12.2	Key Market Forecast Assumptions
12.3	Market Outlook
12.4	Conjoint Analysis
12.5	Total Market Size of NTM Infections in the US
12.5.1	Total Market Size of NTM Infections
12.5.2	The Market Size of NTM Infections by Therapies
13	Key Opinion Leaders' Views
14	SWOT Analysis
15	Unmet Needs
16	Market Access and Reimbursement
16.1	The United States
16.1.1	Centre for Medicare & Medicaid Services (CMS)
17	Appendix
17.1	Bibliography
17.2	Acronyms and Abbreviations
17.3	Report Methodology
18	DelveInsight Capabilities
19	Disclaimer
20	About DelveInsight

Related Reports

Nontuberculous Mycobacterial Infection Epidemiology Forecast

Nontuberculous Mycobacterial Infection Epidemiology Forecast – 2032
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Nontuberculous Mycobacterial Infection epidemiology trends.

Nontuberculous Mycobacterial Infection Pipeline

Nontuberculous Mycobacterial Infection Pipeline Insight – 2024
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key
nontuberculous mycobacterial infection
companies, including Mannkind Corporation, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, among others.

Chronic Obstructive Pulmonary Disease
Market

Chronic Obstructive Pulmonary Disease
Market Insights, Epidemiology, and Market Forecast – 2034
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease
companies, including Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, among others.

Asthma
Market

Asthma
Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc. , among others.

About
DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform
PharmDelve .

Contact Us
Shruti Thakur
[email protected]
+14699457679

Logo:

SOURCE DelveInsight Business Research, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN11092024003732001241ID1108664088